A new letter in The Lancet raises concerns about the EMPHASIS trial, which found a modest increase in 90-day functional outcomes with a 4.5-day minocycline course for acute ischaemic stroke. The authors agree that neuroprotective strategies must be interpreted within the context of statistical robustness, background therapy, patient selection, and generalisability.
The correspondents, Sherief Ghozy and colleagues, highlight that while the study re-examines neuroprotection in the reperfusion era, several design features temper confidence in its immediate real-world applicability. This exchange underscores the ongoing debate over how to translate clinical trial results into broader practice.
Specifically, the trial's design includes a 4.5-day minocycline regimen, yet the letter points to limitations without citing alternative data. No new numbers or statistics are provided, leaving the critique at a conceptual level.
The implications for stroke care remain uncertain. Clinicians may hesitate to adopt minocycline based on this trial alone, pending further studies that address these methodological critiques.
The authors' reply calls for caution rather than outright dismissal, maintaining that the EMPHASIS findings still contribute valuable data to the field.